FindTrial
Sign In

Development of non-invasive and objective parameters for predicting the occurrence of chemotherapy-induced peripheral neuropathy (CIPN) in gastrointestinal cancer patients

Usefulness of heart rate variability (HRV) as non-invasive objective parameters for predicting the occurrence of chemotherapy-induced peripheral neuropathy (CIPN) in gastrointestinal cancer patients precribed chemotherapy

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0005353
Enrollment
100
Registered
2020-08-26
Start date
2018-05-28
Completion date
Unknown
Last updated
2022-11-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

University of Ulsan
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Adults over 18 years old 2) Histologically confirmed cancer patients 3) Eastern Cooperative Oncology Group (ECOG) evaluation performance is = 1 4) Patients who are prescribed chemotherapy including platinum, paclitaxel, docetaxel, and vinca alkaloid 5) Patients who understand the purpose of the study and can consent in writing without impairment of cognitive function

Exclusion criteria

Exclusion criteria: 1) Patients with previous history of chemotherapy 2) Patients with diseases that affect other autonomic neuropathy, such as diabetic neuropathy, Parkinson's disease, vitamin B12 deficiency 3) Patients with a history of hospitalization for acute medical history within the last 1 month

Design outcomes

Primary

MeasureTime frame
symptoms of chemotherapy induced peripheral neuropathy;European Organization for Research and Treatment of Cancer quality of life questionnaire 30(EORTC QOL30);European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Chemotherapy-induced peripheral neuropathy 20 items(EORTC QOL-CIPN20);anxiety and depression;electromyography(EMG);epinephrine;heart rate variability (HRV);norepinephrine;cortisol;hs-CRP;nerve growth factor(NGF)—

Secondary

MeasureTime frame
next-generation sequencing(NGS);natural killer cell(NK cell)—

Countries

Korea, Republic of

Contacts

Public ContactAelee Jang

University of Ulsan

jal0008@naver.com+82-52-259-1252

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026